183720-28-7

Basic information

• Product Name: (+/-)-BMS 204352
• Synonyms: (+/-)-BMS 204352;2H-INDOL-2-ONE, 3-(5-CHLORO-2-METHOXYPHENYL)-3-FLUORO-1,3-DIHYDRO-6-(TRIFLUOROMETHYL)-;3-(5-CHLORO-2-METHOXY-PHENYL)-3-FLUORO-6-TRIFLUOROMETHYL-1,3-DIHYDRO-INDOL-2-ONE;3-(5-Chloro-2-methoxyphenyl)-3-fluoro-6-(trifluoromethyl)indolin-2-one
• CAS NO: 183720-28-7
• Molecular Formula: C₁₆H₁₀ClF₄NO₂
• Molecular Weight: 359.7
• Mol File: 183720-28-7.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 436.9±45.0 °C(Predicted)
• Appearance: /
• Density: 1.50±0.1 g/cm3(Predicted)
• PKA: 10.43±0.40(Predicted)
• CAS DataBase Reference: (+/-)-BMS 204352(CAS DataBase Reference)
• NIST Chemistry Reference: (+/-)-BMS 204352(183720-28-7)
• EPA Substance Registry System: (+/-)-BMS 204352(183720-28-7)

Safety Data

• Hazardous Substances Data: 183720-28-7(Hazardous Substances Data)

Usage

Description

(+/-)-BMS 204352, also known as BMS-204352, is a chemical compound that functions as a potent and selective inhibitor of human 11beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1). This enzyme plays a crucial role in the conversion of inactive cortisone into active cortisol in the liver and adipose tissue. By inhibiting 11β-HSD1, (+/-)-BMS 204352 can potentially lower cortisol levels in the body, which may be advantageous in addressing conditions such as metabolic syndrome, diabetes, and obesity.
Used in Pharmaceutical Industry:
(+/-)-BMS 204352 is used as a therapeutic agent for targeting cortisol-related disorders. Its ability to inhibit the enzyme 11β-HSD1 can potentially reduce cortisol levels, making it a promising candidate for treating conditions like metabolic syndrome, diabetes, and obesity. Research on this compound has demonstrated promising results in animal models, indicating its potential effectiveness in managing these health issues. However, further studies are necessary to ensure its safety and efficacy in humans.

Upstream product

• 635305-45-2 2-(5-chloro-2-(methoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 89694-48-4 5-chloro-2-methoxyphenyl boronic acid 
• 183720-52-7 methyl 2-(5-chloro-2-methoxyphenyl)-2-(2-nitro-4-(trifluoromethyl)phenyl)acetate 
• 26939-01-5 5-chloro-2-methoxyphenylacetic acid,methyl ester 
• 367-86-2 1-fluoro-2-nitro-4-trifluoromethyl-benzene 
• 206194-00-5 5-chloro-α-fluoro-2-methoxy-α-[2-nitro-4-(trifluoromethyl)-phenyl]benzeneacetic acid,methyl ester 

Downstream Products

• 187523-36-0 (-)-BMS-204352 
• 187523-35-9 (S)-(+)-3-(5-chloro-2-methoxyphenyl)-3-fluoro-1,3-dihydro-6-(trifluoromethyl)-2H-indol-2-one 
• 607740-72-7 3-(5-chloro-2-methoxy-phenyl)-3-fluoro-1-methylsulfanylmethyl-6-trifluoromethyl-1,3-dihydro-indol-2-one 

Relevant articles and documents

Novel synthesis method for Flindokalner raceme

The invention discloses a novel synthesis method for a Flindokalner raceme. The method comprises the steps: subjecting 3-fluoro-3-(2,2,2-trifluoro-1,1-dihydroxyethyl)-6(trifluoromethyl)2H-indol-2-one, which serves as a raw material, to a bromation reactio

PREPARATION OF 3-FLUORO OXINDOLE DERIVATIVES

The present invention relates to novel itermediates of formula (1) wherein the wavy bond ( SIMILAR SIMILAR ) represents the racemate, the (R)-enantiomer or the (S)-enantiomer; and R is hydrogen, a carboxyl-protecting group or a cation of an addition salt;

Methods for treating hyperactive gastric motility

This invention provides methods and pharmaceutical compositions for treating, inhibiting or preventing hyperactive gastric motility in a mammal utilizing agonists of KCNQ potassium channels, including KCNQ2, KCNQ3, KCNQ4 and KCNQ5 potassium channels, alone or in combination. The hyperactive gastric motility may be associated with maladies including, colitis, irritable bowel syndrome and Crohn's disease. Compounds useful in these methods include the 1,2,4-triamino-benzene derivatives described in U.S. Pat. No. 5,384,330 (Dieter et al.) and the substituted 3-phenyl oxindole compounds described in U.S. Pat. No. 5,565,483 (Hewawasam et al.). Among the preferred compounds of this invention is N-[2-amino-4-(4-fluorobenzylamino)-phenyl]carbamic acid ethyl ester, also referred to as retigabine.